Cargando…

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

PURPOSE: New treatments with novel mechanisms of action and non-overlapping toxicities are needed for patients with metastatic breast cancer. Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a unique toxicity profile. The randomized phase 3 BEACON study that compared EP to tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortés, Javier, Rugo, Hope S., Twelves, Chris, Awada, Ahmad, Perez, Edith A., Im, Seock-Ah, Zhao, Carol, Hoch, Ute, Tomkinson, Denise, Buchanan, James, Tagliaferri, Mary, Hannah, Alison, O’Shaughnessy, Joyce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938835/ https://www.ncbi.nlm.nih.gov/pubmed/27441152 http://dx.doi.org/10.1186/s40064-016-2446-4

Ejemplares similares

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
por: Cortés, Javier, et al.
Publicado: (2017)

Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
por: Sy, S. Kenneth, et al.
Publicado: (2016)

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
por: Sy, Sherwin K. B., et al.
Publicado: (2018)

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
por: Hoch, Ute, et al.
Publicado: (2014)

Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
por: Nagpal, Seema, et al.
Publicado: (2015)

“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy
por: Twelves, Christopher, et al.
Publicado: (2015)

A multidisciplinary approach to optimizing care of patients treated with alpelisib
por: Rugo, Hope S., et al.
Publicado: (2021)

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2007)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2008)

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020)

Radar beacons
por: Roberts, Arthur
Publicado: (1947)

The Beacon Light
Publicado: (1924)

#BeaconsOfLight
por: Drazner, Mark H.
Publicado: (2021)

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
por: Tripathy, Debu, et al.
Publicado: (2014)

Huerta y la Revolución vistos por la esposa de un diplomático en México
por: O'Shaughnessy, Edith, 1870-1939
Publicado: (1971)

A diplomat's wife in Mexico : letters from the American Embassy at Mexico City, covering the dramatic period between October 8th, 1913, and the breaking off of diplomatic relations on April 23rd, 1914, together with an account of the occupation of Vera Cruz
por: O'Shaughnessy, Edith, 1870-1939
Publicado: (1916)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
por: Rugo, Hope S., et al.
Publicado: (2023)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

Molecular Beacons in Diagnostics
por: Tyagi, Sanjay, et al.
Publicado: (2012)

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
por: Ettl, Johannes, et al.
Publicado: (2020)

The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

The truth about economizing for college: shrinking the college tab
por: O'Shaughnessy, Lynn, et al.
Publicado: (2011)

Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database
por: Clowse, Megan E. B., et al.
Publicado: (2018)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018)

Lactate Dehydrogenase: The Beacon of Hope?
por: Pandarathodiyil, Anitha Krishnan, et al.
Publicado: (2022)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice
por: Peterson, Douglas E., et al.
Publicado: (2016)

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)

Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2017)

Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Molecular beacons with intrinsically fluorescent nucleotides
por: Martí, Angel A., et al.
Publicado: (2006)

Beacon technologies: the hitchhiker's guide to the beacosystem
por: Statler, Stephen, et al.
Publicado: (2016)

Engineering Molecular Beacons for Intracellular Imaging
por: Wu, Cuichen Sam, et al.
Publicado: (2012)

Validation of the Calypso Surface Beacon Transponder
por: Belanger, Maxwell, et al.
Publicado: (2016)

Learning iBeacon : build proximity applications for iOS using Apple's groundbreaking iBeacon technology
por: Gilchrist, Craig
Publicado: (2014)

Beacon v2 and Beacon networks: A “lingua franca” for federated data discovery in biomedical genomics, and beyond
por: Rambla, Jordi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qf5ifritehgetv8m194j6c1tf9